Evidence map›Paper›PMID 27738344›Full record

ArticleOncotarget2017

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Marina Borro, Andrea Botticelli, Federica Mazzuca, Elisa Concetta Onesti, Giovanna Gentile, Adriana Romiti, Bruna Cerbelli, Eva Mazzotti, Luca Marchetti, Luana Lionetto and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Deoxypodophyllotoxin, a Lignan fromInternational journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Marina BorroDepartment of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome, Rome, Italy.
Andrea BotticelliDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Federica MazzucaDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Elisa Concetta OnestiDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Giovanna GentileDepartment of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome, Rome, Italy.
Adriana RomitiDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Bruna CerbelliDepartment of Radiological Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
Eva MazzottiDepartment of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy.
Luca MarchettiDepartment of Clinical Oncology, "Sapienza" University of Rome, Rome, Italy.
Luana LionettoAdvanced Molecular Diagnostic, IDI-IRCCS, Rome, Italy.
Maurizio SimmacoDepartment of Neurosciences, Mental Health and Sensory Organs (NESMOS), "Sapienza" University of Rome, Rome, Italy.
Paolo MarchettiAdvanced Molecular Diagnostic, IDI-IRCCS, Rome, Italy.
Sapienza University of Rome · ITIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background5-fluorouracil (5-FU) based chemotherapy is the most common first line regimen used in gastric and gastroesophageal junction cancer, but development of severe toxicity is a main concern in the treatment. The present study is aimed to evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), as a predictive factor for 5-FU toxicity.

methodsPre-treatment 5-FUDR and gene polymorphisms related to 5-FU metabolism (DPYDIVS14+1G>A, MTHFRA1298T or C677T, TMYS TSER) were characterized in gastro-esophageal cancer patients. Association with toxicities was retrospectively evaluated, using multivariate logistic regression analysis.

results107 gastro-esophageal cancer patients were retrospectively analyzed. No relation between gene polymorphisms and toxicity were detected, while low (< 5th centile) and high (> 95th centile) 5-FUDRs were associated with development of grade 3-4 toxicity (OR 11.14, 95% CI 1.09-113.77 and OR 9.63, 95% CI 1.70-54.55, p = 0.002).

conclusionsCompared to currently used genetic tests, the pre-treatment 5-FUDR seems useful in identifying patients at risk of developing toxicity.

Indexed as

AgedAntimetabolites, AntineoplasticDrug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsFemaleFluorouracilGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideRetrospective StudiesStomach NeoplasmsAntimetabolites, AntineoplasticFluorouracil5-FU degradation rate5-FU toxicityDPYDgastro-esophageal cancerphenotypic test

Identifiers

PMID27738344
PMCPMC5355161
OpenAlexW2530059283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.